Patent intelligence · Companies
Company patent strength
Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.
Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.
Why this page exists — and how to read it
Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.
- Investors
- High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
- Founders & operators
- These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
- Corporate & R&D
- Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.
💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.
3,207 foreign filers with 5+ patents · page 41
| # | Filer | Patents↓ | Granted↓ | Lapsed↓ | Pending↓ | Active |
|---|---|---|---|---|---|---|
| 2001 | ENERGY | 7 | 114.3% | 1 | 5 | 2022–2026 |
| 2002 | ENERGY DOME | 7 | 00% | 0 | 7 | 2022–2025 |
| 2003 | ENZYMES | 7 | 00% | 0 | 7 | 2023–2025 |
| 2004 | EQUINOR LOW CARBON UK | 7 | 00% | 0 | 7 | 2025–2025 |
| 2005 | ETA MANUFACTURE HORLOG RE SUISSE | 7 | 342.9% | 0 | 4 | 2022–2025 |
| 2006 | EVOLVED BY NATURE | 7 | 00% | 0 | 7 | 2022–2025 |
| 2007 | EXONETIK | 7 | 00% | 0 | 7 | 2022–2026 |
| 2008 | FAIVELEY TRANSPORT TOURS | 7 | 114.3% | 1 | 5 | 2022–2026 |
| 2009 | FARMHANNONG | 7 | 114.3% | 0 | 6 | 2022–2024 |
| 2010 | FBD BIOLOGICS | 7 | 00% | 0 | 7 | 2024–2026 |
| 2011 | FERROSAN MEDICAL DEVICES A S | 7 | 00% | 1 | 6 | 2022–2026 |
| 2012 | FIBERLEAN TECHNOLOGIES | 7 | 00% | 4 | 3 | 2022–2024 |
| 2013 | FIVE AI | 7 | 228.6% | 0 | 5 | 2021–2024 |
| 2014 | FIVES FCB | 7 | 114.3% | 0 | 6 | 2022–2026 |
| 2015 | FIVES LANDIS | 7 | 00% | 1 | 6 | 2022–2024 |
| 2016 | FLOTTWEG SE | 7 | 457.1% | 0 | 3 | 2022–2025 |
| 2017 | FLOWER TURBINES | 7 | 114.3% | 0 | 6 | 2022–2025 |
| 2018 | FLOWSERVE MANAGEMENT | 7 | 00% | 0 | 7 | 2022–2025 |
| 2019 | FOOTPRINT INTERNATIONAL | 7 | 00% | 0 | 7 | 2022–2024 |
| 2020 | FORESEE PHARMACEUTICALS | 7 | 114.3% | 0 | 6 | 2022–2025 |
| 2021 | FORKBEARD TECHNOLOGIES AS | 7 | 00% | 6 | 1 | 2022–2022 |
| 2022 | GAEASOFT | 7 | 00% | 0 | 7 | 2024–2025 |
| 2023 | GALACTIC | 7 | 114.3% | 6 | 0 | 2022–2023 |
| 2024 | GD MIDEA HEATING AND VENTILATING EQUIPMENT | 7 | 00% | 0 | 7 | 2024–2024 |
| 2025 | GEA FOOD SOLUTIONS WEERT | 7 | 00% | 0 | 7 | 2023–2025 |
| 2026 | GELION TECHNOLOGIES PTY | 7 | 00% | 0 | 7 | 2023–2024 |
| 2027 | GELITA | 7 | 00% | 1 | 6 | 2022–2026 |
| 2028 | GENERAL FUSION | 7 | 114.3% | 0 | 6 | 2021–2025 |
| 2029 | GENESIS SYSTEMS | 7 | 00% | 0 | 7 | 2023–2025 |
| 2030 | GENESYS CLOUD SERVICES HOLDINGS II | 7 | 228.6% | 0 | 5 | 2022–2024 |
| 2031 | GI CELL | 7 | 00% | 3 | 4 | 2022–2023 |
| 2032 | GLEASON PFAUTER MASCHINENFABRIK | 7 | 114.3% | 0 | 6 | 2022–2025 |
| 2033 | GNEUSS | 7 | 00% | 0 | 7 | 2023–2024 |
| 2034 | GOODMAN | 7 | 114.3% | 0 | 6 | 2023–2025 |
| 2035 | GRAM EQUIPMENT A S | 7 | 114.3% | 0 | 6 | 2021–2026 |
| 2036 | GREE ELECTRIC APPLIANCES OF ZHUHAI | 7 | 457.1% | 0 | 3 | 2022–2023 |
| 2037 | GRIMME LANDMASCHINENFABRIK KG | 7 | 114.3% | 0 | 6 | 2022–2025 |
| 2038 | GUANGDONG GIWEE TECHNOLOGY | 7 | 457.1% | 0 | 3 | 2022–2022 |
| 2039 | GUERBET | 7 | 114.3% | 0 | 6 | 2023–2024 |
| 2040 | H C STARCK TUNGSTEN | 7 | 00% | 0 | 7 | 2023–2026 |
| 2041 | HAGEPE INTERNATIONAL | 7 | 571.4% | 0 | 2 | 2022–2024 |
| 2042 | HANGZHOU HIGHLIGHTLL PHARMACEUTICAL | 7 | 114.3% | 0 | 6 | 2022–2025 |
| 2043 | HANNIBAL IP | 7 | 7100% | 0 | 0 | 2022–2022 |
| 2044 | HARMAN BECKER AUTOMOTIVE SYSTEMS | 7 | 114.3% | 0 | 6 | 2022–2024 |
| 2045 | HEIDELBERG PHARMA RESEARCH | 7 | 00% | 2 | 5 | 2022–2025 |
| 2046 | HEM PHARMA | 7 | 114.3% | 0 | 6 | 2022–2025 |
| 2047 | HERAEUS EPURIO | 7 | 114.3% | 0 | 6 | 2023–2025 |
| 2048 | HETTICH FRANKE KG | 7 | 00% | 3 | 4 | 2022–2024 |
| 2049 | HETTICH HEINZE KG | 7 | 00% | 0 | 7 | 2023–2026 |
| 2050 | HIAB | 7 | 00% | 0 | 7 | 2023–2024 |
Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →
Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →